Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositori Institucional UIB
Publication Artículo científico (JournalArticle)

Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage

  • Núñez-Jurado, D.
  • Fernández-Vega, A.
  • Del Río, C.
  • Penalba, A.
  • Llucià-Carol, L.
  • Muiño-Acuña, E.
  • Ezcurra-Díaz, G.
  • Guasch-Jiménez, M.
  • Cullell, N.
  • Serrano-Heras, G.
  • Arias-Salazar, L.
  • Vives-Bauza, C.
  • Tur, S.
  • Urra, X.
  • Castellanos, M.
  • Krupinski, J.
  • Freijo-Guerrero, M.
  • Jiménez-Conde, J.
  • Fernández-Pérez, I.
  • Segura, T.
  • Marti-Fabregas, J.
  • Férnandez-Cadenas, I.
  • Montaner, J.
[eng] Background: Timely differentiation between ischemic stroke (IS) and intracerebral hemorrhage (ICH) is critical for guiding appropriate acute management strategies. While neuroimaging is the diagnostic gold standard, its accessibility is often limited in urgent clinical settings. Blood biomarkers offer a promising, scalable diagnostic alternative; however, no validated panel is yet available for distinguishing stroke subtypes during the hyperacute phase. Methods: In a multicenter study, plasma samples were collected within 6 h of symptom onset. A total of 3,072 proteins were measured using Olink® proximity extension assays. We applied differential expression analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and receiver operating characteristic (ROC) curve evaluation. To interpret the biological relevance of the findings, we conducted functional enrichment and protein-protein interaction (PPI) analyses. Results: Among the 388 patients (344 IS, 44 ICH), 2,531 proteins were retained; 878 reached nominal significance (p < 0.05), and 67 remained significant after multiple-testing correction (FDR-adjusted p < 0.05). Of these, 844 were overexpressed in ICH and 34 in IS. GFAP, a glial marker, emerged as the most discriminative biomarker for ICH versus IS (AUC = 0.887; sensitivity: 80%, specificity: 90%), followed by BCAN (AUC = 0.820), SNAP25 (AUC = 0.797), and SPOCK1 (AUC = 0.786). For IS, S100A12 (AUC = 0.677) and MNDA (AUC = 0.657) showed the best performance. Multivariate analyses confirmed the presence of distinct proteomic patterns, with enrichment revealing a significant overrepresentation of neurodevelopmental and synaptic pathways. In PPI networks, GFAP and LYN emerged as central hubs. Conclusion: This study reveals a robust plasma proteomic signature distinguishing IS from ICH within hours of onset. These results lay the groundwork for scalable, blood-based diagnostics to guide early stroke management when imaging is delayed or unavailable.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage

  • Núñez-Jurado, David
  • Fernández-Vega, Alejandro
  • del Río, Carmen
  • Penalba, Anna
  • Llucià-Carol, Laia
  • Muiño-Acuña, Elena
  • Ezcurra-Díaz, Garbiñe
  • Guasch, Marina
  • Cullel, Natalia
  • Serrano-Heras, Gemma
  • Arias-Salazar, Lourdes
  • Vives-Bauza, Cristófol
  • Tur, Silvia
  • Urra, Xabier
  • Castellanos, María del Mar
  • Krupinski, Jerzy
  • Freijo Guerrero, María del Mar
  • Jiménez-Conde, Jordi
  • Fernández-Pérez, Isabel
  • Segura, Tomás
  • Martí-Fàbregas, Joan
  • Fernández-Cadenas, Israel
  • Montaner, Joan
[Abstract] Background: Timely differentiation between ischemic stroke (IS) and intracerebral hemorrhage (ICH) is critical for guiding appropriate acute management strategies. While neuroimaging is the diagnostic gold standard, its accessibility is often limited in urgent clinical settings. Blood biomarkers offer a promising, scalable diagnostic alternative; however, no validated panel is yet available for distinguishing stroke subtypes during the hyperacute phase. Methods: In a multicenter study, plasma samples were collected within 6 h of symptom onset. A total of 3,072 proteins were measured using Olink® proximity extension assays. We applied differential expression analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and receiver operating characteristic (ROC) curve evaluation. To interpret the biological relevance of the findings, we conducted functional enrichment and protein-protein interaction (PPI) analyses. Results: Among the 388 patients (344 IS, 44 ICH), 2,531 proteins were retained; 878 reached nominal significance (p < 0.05), and 67 remained significant after multiple-testing correction (FDR-adjusted p < 0.05). Of these, 844 were overexpressed in ICH and 34 in IS. GFAP, a glial marker, emerged as the most discriminative biomarker for ICH versus IS (AUC = 0.887; sensitivity: 80%, specificity: 90%), followed by BCAN (AUC = 0.820), SNAP25 (AUC = 0.797), and SPOCK1 (AUC = 0.786). For IS, S100A12 (AUC = 0.677) and MNDA (AUC = 0.657) showed the best performance. Multivariate analyses confirmed the presence of distinct proteomic patterns, with enrichment revealing a significant overrepresentation of neurodevelopmental and synaptic pathways. In PPI networks, GFAP and LYN emerged as central hubs. Conclusion: This study reveals a robust plasma proteomic signature distinguishing IS from ICH within hours of onset. These results lay the groundwork for scalable, blood-based diagnostics to guide early stroke management when imaging is delayed or unavailable., This work was funded by the National Institute of Health Carlos III (ISCIII) under the framework of Health Research Projects (PMP21/00165, PREVICTUS; and PI21/01158, ETNIAS) and co-funded by the European Union. D.N-J. was supported by a Río Hortega contract (CM23/00216) from the ISCIII. C.R. was supported by the applied research and innovation project POLIFENEV, co-funded by the European Union – Ministry of Finance and Civil Service – European Funds – Regional Government of Andalusia – Ministry of University, Research and Innovation.A.F-V. was supported by a contract funded through the CRESCENDO project (grant AC22/00005) from the ISCIII. This work was supported by project RD21/0006/0015 and RD24/0009/0007, funded by the ISCIII with public funding from the Cooperative Research Networks for Health Results (RICORS) RICORS-ICTUS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Association of A1AT With Poor Functional Outcome in Patients With Acute Ischemic Stroke

  • García-Rodríguez, Paula
  • Lamana-Vallverdú, Marcel
  • Guamán-Pilco, Daisy R.
  • Penalba, Anna
  • Ramiro, Laura
  • Simats, Alba
  • Faura, Júlia
  • Bustamante, Alejandro
  • Díaz-Troyano, Noelia
  • Montaner, Joan
[Background] This study aimed to investigate whether A1AT (α‐1 antitrypsin) bloodstream levels, measured acutely after ischemic stroke, can predict the outcome of patients with stroke., [Methods and Results] Two cohorts of patients with stroke were studied independently and retrospectively: a pilot cohort of 59 patients and a larger replicative study with 527 patients. Blood samples were drawn at hospital admission (<6 hours after stroke onset) before any treatment was given. A1AT levels were analyzed. Patients were followed after the event, and functional outcomes were evaluated at in‐hospital (discharge) and midterm (third month) follow‐up according to the modified Rankin Scale (considering modified Rankin Scale score >2 a poor outcome). Association studies between A1AT levels and functional outcomes were conducted. We also evaluated the added value of A1AT as a prognostic biomarker over the clinical model (sex, age, premorbid modified Rankin Scale and National Institutes of Health Stroke Scale scores) with the likelihood ratio test. In both studies, the levels of A1AT were higher in patients who had worse outcomes, were older, and had higher National Institutes of Health Stroke Scale scores at admission. In the pilot study, higher levels of A1AT were also associated with death at discharge and at 3 months after stroke (P=0.035 and P=0.023, respectively). The addition of A1AT to the clinical model did not show enough evidence of increasing the fit of the model to the data in either cohort., [Conclusions] Based on our data, we cannot claim that A1AT is an independent biomarker of ischemic stroke. Nevertheless, A1AT is potentially involved in stroke outcomes and might be explored as a potential therapeutic target., The Neurovascular Research Laboratory takes part in the Redes de Investigación Cooperativa Orientadas a Resultados en Salud‐ICTUS Enfermedades Vasculares Cerebrales Network, Instituto de Salud Carlos III), Spain (RD21/0006/0007), and acknowledges funding for this project by a PI21/01158 grant from Fondos Semilla Dr Miguel Blanco of the Instituto de Salud Carlos III. A.B. received funding from Instituto de Salud Carlos III (INT22/00068), cofinanced by the Fondo Europeo de Desarrollo Regional., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage

  • Núñez Jurado, David
  • Fernández-Vega, Alejandro
  • Del Río, Carmen
  • Penalba, Anna
  • Llucià-Carol, Laia
  • Muiño-Acuña, Elena
  • Ezcurra-Díaz, Garbiñe
  • Guasch-Jiménez, Marina
  • Cullell, Natalia
  • Serrano-Heras, Gemma
  • Arias-Salazar, Lourdes
  • Vives-Bauza, Cristòfol
  • Tur, Silvia
  • Urra, Xabier
  • Castellanos, Mar
  • Krupinski, Jerzy
  • Freijo-Guerrero, Marimar
  • Jiménez-Conde, Jordi
  • Fernández-Pérez, Isabel
  • Segura, Tomás
  • Marti-Fabregas, Joan
  • Férnandez-Cadenas, Israel
  • Montaner, Joan
[Background] Timely differentiation between ischemic stroke (IS) and intracerebral hemorrhage (ICH) is critical for guiding appropriate acute management strategies. While neuroimaging is the diagnostic gold standard, its accessibility is often limited in urgent clinical settings. Blood biomarkers offer a promising, scalable diagnostic alternative; however, no validated panel is yet available for distinguishing stroke subtypes during the hyperacute phase., [Methods] In a multicenter study, plasma samples were collected within 6 h of symptom onset. A total of 3,072 proteins were measured using Olink® proximity extension assays. We applied differential expression analysis, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and receiver operating characteristic (ROC) curve evaluation. To interpret the biological relevance of the findings, we conducted functional enrichment and protein–protein interaction (PPI) analyses., [Results] Among the 388 patients (344 IS, 44 ICH), 2,531 proteins were retained; 878 reached nominal significance (p < 0.05), and 67 remained significant after multiple-testing correction (FDR-adjusted p < 0.05). Of these, 844 were overexpressed in ICH and 34 in IS. GFAP, a glial marker, emerged as the most discriminative biomarker for ICH versus IS (AUC = 0.887; sensitivity: 80%, specificity: 90%), followed by BCAN (AUC = 0.820), SNAP25 (AUC = 0.797), and SPOCK1 (AUC = 0.786). For IS, S100A12 (AUC = 0.677) and MNDA (AUC = 0.657) showed the best performance. Multivariate analyses confirmed the presence of distinct proteomic patterns, with enrichment revealing a significant overrepresentation of neurodevelopmental and synaptic pathways. In PPI networks, GFAP and LYN emerged as central hubs., [Conclusion] This study reveals a robust plasma proteomic signature distinguishing IS from ICH within hours of onset. These results lay the groundwork for scalable, blood-based diagnostics to guide early stroke management when imaging is delayed or unavailable., This work was funded by the National Institute of Health Carlos III (ISCIII) under the framework of Health Research Projects (PMP21/00165, PREVICTUS; and PI21/01158, ETNIAS) and co-funded by the European Union. D.N-J. was supported by a Río Hortega contract (CM23/00216) from the ISCIII. C.R. was supported by the applied research and innovation project POLIFENEV, co-funded by the European Union – Ministry of Finance and Civil Service – European Funds – Regional Government of Andalusia – Ministry of University, Research and Innovation.A.F-V. was supported by a contract funded through the CRESCENDO project (grant AC22/00005) from the ISCIII. This work was supported by project RD21/0006/0015 and RD24/0009/0007, funded by the ISCIII with public funding from the Cooperative Research Networks for Health Results (RICORS) RICORS-ICTUS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Subchronic 90-days toxicity profile of Salicornia ramosissima extract in rats

  • Romero-Bernal, Marina
  • González-Díaz, Ángela
  • Tripodi, Maria
  • Álvarez, Alba Zheli
  • Rodríguez, Jara
  • Núñez Jurado, David
  • Cádiz-Gurrea, María de la Luz
  • Prieto, Ana I.
  • Diez‐Quijada, Leticia
  • Cantarero, Irene
  • Río, Carmen del
  • Montaner, Joan
Salicornia ramosissima, a halophytic plant rich in bioactive compounds, has gained attention for its potential health benefits. However, its long-term safety profile remains underexplored. This study aimed to evaluate the subchronic 90-day toxicity of S. ramosissima extract in Wistar rats. Animals received daily oral doses of 100, 500 or 1.000 mg/kg/day of the extract or placebo, and key physiological, biochemical, and histopathological parameters were assessed. Results indicated no significant adverse effects on body weight, food and water intake, or organ weights. Hematological and biochemical analyses revealed no major toxicological concerns. Histopathological examination did not indicate any extract-induced lesions in any of the examined organs, which included gastrointestinal, respiratory, lymphoid, urinary, nervous, circulatory and reproductive systems. Complementary assays demonstrated absence of developmental toxicity in Drosophila melanogaster and no mutagenic activity in the Ames test. Overall, these results indicate that subchronic administration of S. ramosissima extract is well tolerated in rats and does not elicit genotoxic or developmental toxicity, supporting its potential safe use as a functional food or nutraceutical ingredient., This work was supported by ISCIII under the framework of Health Research Projects (PI21/01158 ETNIAS), and co-funded by the European Union. M.R. received financial support from the PFIS program funded by ISCIII grant number FI22/00202. This work was supported by project RD21/0006/0015, funded by the National Institute of Health Carlos III (ISCiii) with public funding from the Cooperative Research Networks for Health Results (RICORS) RICORS-ICTUS. Thematic Area: cerebrovascular diseases. “Funded by the European Union – NextGenerationEU. European Union Recovery and Resilience Facility, measures integrated into the PRTR”. This work is part of the research and applied innovation project POLIFENEV, co-financed by the EU - Ministry of Finance and Public Function - European Funds - Junta de Andalucía – Ministry of University, Research, and Innovation awarded to C.R. D.N.J. received financial support from the Rio Hortega program funded by ISCIII, grant number CM23/00216., Peer reviewed